These materials are for personal use only and not for reproduction.

Note that the poster includes new data and is entitled “Exploratory Subgroup Outcomes in the Phase 3 KEYNOTE-B15 Study of Neoadjuvant-Adjuvant Enfortumab Vedotin Plus Pembrolizumab for Participants With Muscle-Invasive Bladder Cancer Eligible for Cisplatin”.